Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Sponsors › Genomics: Clinical Implementation › Foundation Medicine Liquid Biopsy Gets FDA Approval for Multiple Companion Diagnostic Indications

Foundation Medicine Liquid Biopsy Gets FDA Approval for Multiple Companion Diagnostic Indications

Aug 27, 2020
|
staff reporter

NEW YORK – The US Food and Drug Administration has approved Foundation Medicine's FoundationOne Liquid CDx, a multi-cancer comprehensive liquid-biopsy test, for multiple companion diagnostic indications including one for prostate cancer and three for lung cancer.

The approval is the agency's second for a comprehensive liquid biopsy, following on the heels of a nod earlier this month for Guardant Health's Guardant360 CDx test.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Sep
24
Featured Webinar

New Insights Underscore the Need to Identify NTRK Fusions in Childhood Tumors

NTRK fusions are oncogenic drivers in a variety of tumors.

Oct
08
Featured Webinar

Novel Applications of RNA-based Precision Oncology: From Drug Tolerability to Immunogenomics

Sponsored by
Genecentric

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Oct
14
Featured Webinar

Application of ctDNA Analysis to Detect MRD and Predict Recurrence in Colorectal Cancer

Sponsored by
Inivata

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.

Oct
15
Featured Webinar

A Comparison of cfDNA Approaches to Guide Targeted Therapy in NSCLC

In non-small cell lung cancer (NSCLC), early detection of emerging resistance mutations such as EGFR T790M is important in order to determine the appropriate targeted therapeutic strategy.

What's Popular?

In Cancer

  1. Startup Stitch Bio Bets on CRISPR Tech to Render Cancer Cells With Gene Fusions Druggable

    Premium

  2. Pfizer Pursuing Multiple Biomarker-Defined Cancer Indications in Coming Years

    Premium

  3. Foundation Medicine, Takeda Collaborate to Develop CDx for NSCLC Therapies

  4. BMS' Opdivo Garners Positive Draft Recommendation From UK's NICE in Second-Line NSCLC

  5. Yufan Biotech, Abound Bio Partner on HPK1-Inhibiting CAR T-Cell Therapies

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.